CL2017002066A1 - Proteasas de cisteína - Google Patents

Proteasas de cisteína

Info

Publication number
CL2017002066A1
CL2017002066A1 CL2017002066A CL2017002066A CL2017002066A1 CL 2017002066 A1 CL2017002066 A1 CL 2017002066A1 CL 2017002066 A CL2017002066 A CL 2017002066A CL 2017002066 A CL2017002066 A CL 2017002066A CL 2017002066 A1 CL2017002066 A1 CL 2017002066A1
Authority
CL
Chile
Prior art keywords
cysteine proteases
live
igg
methods
novedous
Prior art date
Application number
CL2017002066A
Other languages
English (en)
Inventor
Christian Kjellman
Sofia Jarnum
Emma Nordahl
Original Assignee
Hansa Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Medical Ab filed Critical Hansa Medical Ab
Publication of CL2017002066A1 publication Critical patent/CL2017002066A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A UN POLIPÉPTIDO NOVEDOSO QUE EXHIBE ACTIVIDAD DE PROTEASA DE CISTEÍNA DE IgG Y USOS IN VIVO Y EX VIVO DE LOS MISMOS. USOS DEL POLIPÉPTIDO INCLUYEN MÉTODOS PARA LA PREVENCIÓN O TRATAMIENTO DE ENFERMEDADES Y AFECCIONES MEDIADAS POR IqG, Y MÉTODOS PARA EL ANÁLISIS DE IgG.</p>
CL2017002066A 2015-02-12 2017-08-11 Proteasas de cisteína CL2017002066A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201502305A GB201502305D0 (en) 2015-02-12 2015-02-12 Protein

Publications (1)

Publication Number Publication Date
CL2017002066A1 true CL2017002066A1 (es) 2018-02-02

Family

ID=52781455

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002066A CL2017002066A1 (es) 2015-02-12 2017-08-11 Proteasas de cisteína

Country Status (28)

Country Link
US (3) US10758597B2 (es)
EP (2) EP3256579B1 (es)
JP (1) JP6879921B2 (es)
KR (1) KR102524594B1 (es)
CN (2) CN107532158A (es)
AU (1) AU2016217801B2 (es)
BR (1) BR112017017286A2 (es)
CA (1) CA2976016C (es)
CL (1) CL2017002066A1 (es)
CO (1) CO2017009060A2 (es)
DK (1) DK3256579T3 (es)
EA (1) EA035896B1 (es)
ES (1) ES2962794T3 (es)
FI (1) FI3256579T3 (es)
GB (1) GB201502305D0 (es)
HR (1) HRP20231496T1 (es)
HU (1) HUE064122T2 (es)
IL (1) IL253939B (es)
LT (1) LT3256579T (es)
MX (1) MX2017010389A (es)
MY (1) MY187486A (es)
PL (1) PL3256579T3 (es)
PT (1) PT3256579T (es)
RS (1) RS64840B1 (es)
SG (1) SG11201706349YA (es)
SI (1) SI3256579T1 (es)
WO (1) WO2016128559A1 (es)
ZA (1) ZA201705114B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CN108410798A (zh) * 2018-03-27 2018-08-17 福建三造血技术有限公司 细胞分离用微珠洗脱液及配制方法
KR20210006357A (ko) 2018-04-03 2021-01-18 스트라이드바이오 인코포레이티드 항체-회피 바이러스 벡터
WO2020102740A2 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
US20220143213A1 (en) * 2019-01-28 2022-05-12 Duke University Composition and Methods for Evading Humoral Immunity
KR20220011616A (ko) 2019-03-21 2022-01-28 스트라이드바이오 인코포레이티드 재조합 아데노 관련 바이러스 벡터
US20220347298A1 (en) 2019-10-04 2022-11-03 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
EP4045525A1 (en) 2019-10-17 2022-08-24 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
BR112021025769A2 (pt) 2019-12-06 2022-04-12 Regeneron Pharma Composições de proteína anti-vegf e métodos para a produção das mesmas
WO2021151004A1 (en) * 2020-01-22 2021-07-29 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
GB202002072D0 (en) 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
US20230054144A1 (en) 2020-02-14 2023-02-23 Ultragenyx Pharmaceutical Inc. Gene therapy for treating cdkl5 deficiency disorder
GB202003129D0 (en) 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
GB202007434D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
EP4162951A1 (en) 2020-06-05 2023-04-12 Shanghai Bao Pharmaceuticals Co., Ltd. Pharmaceutical composition of enzymes and viruses and application thereof
WO2022057942A1 (zh) * 2020-09-21 2022-03-24 上海宝济药业有限公司 一种药物组合及其应用
EP4225382A2 (en) 2020-10-07 2023-08-16 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
FR3125965A1 (fr) * 2021-08-05 2023-02-10 Mc Saf Conjugués anticorps-médicament
WO2023019168A1 (en) 2021-08-11 2023-02-16 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
AU2022385450A1 (en) 2021-11-15 2024-06-13 Hansa Biopharma AB Methods for enhancing adoptive cell transfer immunotherapies
EP4275701A1 (en) 2022-05-13 2023-11-15 Hansa Biopharma AB Conditioning regimen for cell transplant
EP4302770A1 (en) 2022-07-08 2024-01-10 Hansa Biopharma AB Regimen for enzymatic desensitisation
WO2024057095A1 (en) 2022-09-14 2024-03-21 Genovis Ab Mutant protease
EP4349365A1 (en) 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy
CN115873833A (zh) * 2022-11-08 2023-03-31 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺
CN115998690A (zh) * 2022-11-10 2023-04-25 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA2421278A1 (en) * 1998-03-11 1999-09-16 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
WO2002050107A2 (en) 2000-12-21 2002-06-27 Shire Biochem Inc. Streptococcus pyogenes antigens and corresponding dna fragments
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
CN105770871A (zh) 2005-06-09 2016-07-20 汉莎医药有限公司 IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途
GB0624874D0 (en) * 2006-12-13 2007-01-24 Hansa Medical Ab Treatment
US8323908B2 (en) 2007-09-14 2012-12-04 Genovis Ab Method of assessing glycosylation state or functional quality of an IgG containing sample
JP2011506433A (ja) 2007-12-13 2011-03-03 インターバック アーベー 改変された免疫組成物
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
US20110294150A1 (en) 2009-02-09 2011-12-01 Hans Koll Immunoglobulin glycosylation pattern analysis
CA2799136A1 (en) * 2010-05-26 2011-12-01 Intervacc Ab Vaccine against streptococcal infections based on recombinant proteins
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
GB201316744D0 (en) 2013-09-20 2013-11-06 Genovis Ab Method
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

Also Published As

Publication number Publication date
ES2962794T3 (es) 2024-03-21
KR20170110153A (ko) 2017-10-10
PL3256579T3 (pl) 2024-02-26
FI3256579T3 (fi) 2023-11-13
IL253939A0 (en) 2017-10-31
BR112017017286A2 (pt) 2018-04-17
US10758597B2 (en) 2020-09-01
SI3256579T1 (sl) 2024-01-31
AU2016217801B2 (en) 2022-03-17
HUE064122T2 (hu) 2024-03-28
US20230302100A1 (en) 2023-09-28
CO2017009060A2 (es) 2018-01-16
LT3256579T (lt) 2023-11-27
EP3256579A1 (en) 2017-12-20
MX2017010389A (es) 2017-12-07
MY187486A (en) 2021-09-24
PT3256579T (pt) 2023-11-23
CN107532158A (zh) 2018-01-02
IL253939B (en) 2020-01-30
DK3256579T3 (en) 2023-11-20
KR102524594B1 (ko) 2023-04-21
ZA201705114B (en) 2024-01-31
AU2016217801A1 (en) 2017-08-10
CN113564150A (zh) 2021-10-29
WO2016128559A1 (en) 2016-08-18
EP3256579B1 (en) 2023-08-30
EA035896B1 (ru) 2020-08-27
JP2018510622A (ja) 2018-04-19
RS64840B1 (sr) 2023-12-29
CA2976016A1 (en) 2016-08-18
US20180037962A1 (en) 2018-02-08
SG11201706349YA (en) 2017-09-28
GB201502305D0 (en) 2015-04-01
US20200179497A1 (en) 2020-06-11
JP6879921B2 (ja) 2021-06-02
US11524057B2 (en) 2022-12-13
EA201791775A1 (ru) 2018-02-28
CA2976016C (en) 2023-08-29
HRP20231496T1 (hr) 2024-03-01
EP4265719A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
CL2017002066A1 (es) Proteasas de cisteína
CO2017009061A2 (es) Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenes
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
BR112018008901A8 (pt) formulações subcutâneas de anticorpos anti-cd 38 e seus usos
GT201600249A (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
EA201792583A1 (ru) Способы и композиции для ингибирования взаимодействия менина с белками mll
EA201691582A1 (ru) Новые фармацевтические препараты
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
CL2019000609A1 (es) Variantes de alfa-glucosidasa ácida y usos de las mismas.
ECSP17023281A (es) Inhibidores de mk2 y sus usos
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
CR20170219A (es) Inhibidores del bromodominio
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
CL2019000610A1 (es) Variantes de alfa-glucosidasa ácida y usos de las mismas.
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
BR112017015880A2 (pt) anticorpos, usos e métodos
DOP2017000260A (es) Piroglutamato de vortioxetina
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
BR112017004893A2 (pt) composições e métodos para o tratamento de lesões cutâneas pré-cancerosas
BR112018002382A8 (pt) Novos anticorpos anti-gvpi humano e usos dos mesmos
CR20160316A (es) Compuestos derivados de hidroxiformamida y usos del mismo
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia